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Abstract: Chiral amines are important components of 40–45% of small molecule pharmaceuticals
and many other industrially important fine chemicals and agrochemicals. Recent advances in
synthetic applications ofω-transaminases for the production of chiral amines are reviewed herein.
Although a new pool of potentialω-transaminases is being continuously screened and characterized
from various microbial strains, their industrial application is limited by factors such as disfavored
reaction equilibrium, poor substrate scope, and product inhibition. We present a closer look at
recent developments in overcoming these challenges by various reaction engineering approaches.
Furthermore, protein engineering techniques, which play a crucial role in improving the substrate
scope of these biocatalysts and their operational stability, are also presented. Last, the incorporation
of ω-transaminases in multi-enzymatic cascades, which significantly improves their synthetic
applicability in the synthesis of complex chemical compounds, is detailed. This analysis of recent
advances shows thatω-transaminases will continue to provide an efficient alternative to conventional
catalysis for the synthesis of enantiomerically pure amines.
Keywords: biocatalysis; chiral amines;ω-transaminases; protein engineering; reaction engineering;
multi-enzymatic cascades
1. Introduction
Enantiomerically pure amines are indispensable constituents of various small molecule
pharmaceuticals, fine chemicals, and agrochemicals [1]. The increasing demands for enantiopure
compounds in the pharmaceutical, fine chemicals, and agricultural industries, together with the
environmental restrictions approved by many economies, require the effective integration of traditional
chemical synthesis methods with those of enzymatic ‘greener’ approaches [2–5]. The chemical synthesis
of chiral amines is labor intensive, requiring harsh reaction conditions and use of toxic intermediates.
The use of toxic metals also warrants a purification step, thus further complicating the synthetic
systems and the cost thereof [6]. As enzymes are obtained from renewable resources, they fulfil the
basic demands of sustainable and green chemistry, proposed by Graedel et al. [7]. In this context,
biocatalysis, the application of enzymes for efficient and selective chemical transformations, has been
recognized as a major ‘green technology’ that provides sustainable synthetic methods towards a range
of chiral compounds [8,9].
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Transaminases (TAs) are one of the largest groups of enzymes used in the synthesis of chiral
amine building blocks [10–13]. As TAs play key roles in various cellular signaling and metabolic
pathways, their presence is ubiquitous in nature [14]. The history of transamination can be traced back
to 1930, when Needham and coworkers observed the relationship between levels of amino acids such
as L-glutamic acid, L-aspartic acid and oxaloacetic acid in the breast muscles of pigeon [15]. Since the
first demonstration of transamination in the late 1930s, various transaminases have been discovered in
subsequent decades [16,17]. Depending on their specificities towards various substrates, transaminases
are generally classified as α- or ω-TAs. Transaminases are classified based on the structures of the
amino donor substrates, which are divided based on the presence and position of a negatively charged
group with respect to the amino group being transferred. In the case of α-Transaminases (i.e., amino
acid TAs), the presence of a carboxylic acid group in the α-position to the keto or amine functionality
is exclusively required [18]. ω-TAs transfer an amino group attached to a primary carbon at least one
carbon away from a carboxyl group (Figure 1). In addition, compounds lacking any carboxyl groups,
such as amines and ketones, can serve as substrates forω-TAs, thus making these enzymes potential
biocatalysts for the synthesis of chiral amine compounds [18–20]. ω-TAs accepting amines/ketones
without carboxylic group are interchangeably referred to as amino transaminases.
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Figure 1. Schematic of transamination catalyzed by transaminases.
The mechanism of the ω-TA-catalyzed transamination reaction is well studied and has been
reported to exhibit ping-pong-bi-bi kinetics. In a two-step reaction, Pyridoxal 5′-phosphate (PLP),
bound to the lysine residue of an enzyme, mediates the transfer of amino group from an amino donor,
such as L-alanine to form pyridoxamine phosphate (PMP) intermediate. Subsequently, this amine
group is transferred to the amino acceptor, such as a keto acid or ketone and the PLP is regenerated
for the next catalytic cycle [12,18,21]. The enantiomeric purity of the stereospecific isomer formed
by TA-mediated biocatalysis is a consequence of their exclusive substrate-binding mode, which is
constrained by the relative position of PLP and two substrate-binding pockets of different sizes.
PLP-dependent enzymes are divided into seven Fold-Types (I–VII) and despite their wide
substrate specificities, ω-transaminases are only found in two different protein folds: (S)-selective
enzymes, which belong to protein fold-type I and (R)-selective enzymes belonging to protein fold-type
IV) [19,20,22].
2. Synthetic Approaches for Chiral Amines and Equilibrium Shift forω-TA-Mediated Biocatalysis
ω-TAs can be employed for the synthesis of enantiopure amines using three approaches: (A)
kinetic resolution of the racemic mixture of amines; (B) asymmetric synthesis using pro-chiral ketones
and (C) deracemization of racemic amines (Figure 2). The previous two decades have seen a surge of
interest in TA-mediated amination reactions.
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Figure 2. Synthetic approaches for ω-TA-mediated amine synthesis: (A) Kinetic resolution with
(S)-ω-TA; (B) Asymmetric synthesis and (C) Deracemization of racemic amine using (R)-ω-TA and
(S)-ω-TA. (Adapted from [14], Copyright (2010), with permission from Elsevier).
2.1. Kinetic Resolution
The kinetic resolution of primary amines employs stoichiometric amounts of an amino acceptor,
wherein the reaction equilibrium favors product formation. Since the early 1990s, when Celgene
Corporation successfully used kinetic resolution for the synthesis of enantiopure amines [23],
this approach has been extensively explored in the last few years [15,24–28].
With the developing substrate scope and improved enzymatic characteristics, many “ready to
use” screening toolkits are commercially available for their application in biocatalysis. For instance,
commercially availableω-TAs fromCodexis such as ATA-256, ATA-114, ATA-117, ATA-113, and ATA-103
have been successfully applied for the synthesis of chiral amines [12,29,30]. In addition, a new pool of
potential TAs is being continuously screened and characterized from various microbial strains [31,32].
Recently, an (S)-ω-transaminase from the thermophilic eubacterium Sphaerobacter thermophilus was
expressed and functionally characterized in Yun’s laboratory [33]. This thermostable enzyme was used
for the kinetic resolution of various amines, and β- and γ-amino acids, in the presence of pyruvate as
amino acceptor. Wu et al. have characterized four new distinctω-TAs from Pseudomonas putidaNBRC
14164, which were utilized for the kinetic resolution of racemic amines such as 4-phenylbutan-2-amine,
2,3-dihydro-1H-inden-1-amine and amino alcohols such as 2-amino-2-phenylethanol, 2-aminobutan-1-ol,
etc. [24]. More recently, Iglesias et al. [34] characterized an (R)-ω-TA from Caproniasemi immersa.
In their studies, whole cell extracts of E. coli BL21 (DE3) expressing (R)-ω-TA were utilized for the
resolution of several racemic amines in the presence of pyruvic acid as an amine acceptor. Most recently,
Baud et al. used a metagenomics approach for the discovery of new ω-TAs and subsequently for
the synthesis of allylic amines [35]. Three enzymes were selected among the 11 putative class-III
TAs identified by genome mining. These enzymes were further evaluated for their transamination
potential of functionalized cinnamaldehydes, which are ultimately used as building blocks for antifungal
Naftin® (naftifine) and analogs thereof [35]. Gao et al. also identified and characterized a novel
Catalysts 2018, 8, 254 4 of 25
(R)-enantioselectiveω-TA from Fusarium oxysporum by genome mining and evaluated it for the kinetic
resolution of amine substrates, such as 1-(3-chlorophenyl)ethanamine, 1-(2-fluorophenyl)ethanamine
and (4-chlorophenyl)(phenyl)methanamine [36].
Although kinetic resolution is advantageous in requiring only a single enzyme, the atom
efficiency of kinetic resolution remains low with a maximum theoretical yield of 50% [15]. The kinetic
resolution also suffers other disadvantages, such as the formed ketone-product from corresponding
amines being reported to cause severe inhibition [14]. Thus, the removal of formed ketone to
circumvent product inhibition is highly desirable (Figure 3(AI)). Various strategies, such as physical
extraction/vaporization, are available to remove the ketone products and thus to shift the equilibrium
of the reversible reaction towards product formation [37] (Figure 3). Accordingly, isopropylamine has
been identified as an industrial choice, since it is readily available and economically viable, and its
product acetone is volatile and can easily be removed by reduced pressure (Figure 3(AII)) [34,38,39].
However, complete removal of low concentrations of acetone (<100 mM), without removing other
volatile components of the reaction, is a challenging task.

Ν
 
Figure 3. Various strategies used to shift the equilibrium of ω-TA mediated transamination: (AI)
Removal of ketone byproduct by evaporation; (AII) Removal of ketone byproduct under reduced
pressure; (AIII) Removal of ketone byproduct using biphasic reaction system; (B) Recycling of pyruvate
substrate; and (C) Use of ‘smart’ amine donors (BCTA- Branched-chain amino acid transaminases;
LDH-Lactate dehydrogenase; GDH-Glucose dehydrogenase).
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It has also been reported that the removal of ketones by physical methods is critically affected by
the equilibrium constant and volatility of the ketones. Owing to the differential polarities of amines
and ketones, methods such as extraction using bi-phasic reactions systems, either liquid-solid or
liquid-liquid, have been developed for the continuous removal of ketone products (Figure 3(AIII)) [40].
However, extraction using organic/aqueous biphasic systems is limited by the denaturation of
enzymes in an organic environment and the poor discrimination between substrate and product [12].
Nonetheless, to avoid enzyme denaturation in biphasic systems, stabilization of enzymes by
immobilization [41,42] (detailed in Section 4.3), enzyme membrane- and packed bed reactors have also
been reported [15,43,44].
2.2. Asymmetric Synthesis
The maximum theoretical yield of 50% limits the practical applications of the kinetic resolution
approach. Thus, despite being more challenging than kinetic resolution, asymmetric synthesis
and deracemization are preferred strategies, as they can generate a theoretical yield of 100% [45].
In asymmetric synthesis, prochiral ketones are aminated to the corresponding chiral amines, with the
possibility of obtaining the desired enantiopure amine form in 100% yield [14].
Other than an industrially applied procedure for antidiabetic Sitagliptin, the recent successful
examples of amine synthesis by ω-TA-mediated catalysis include pyridyl alkylamines [46],
(R)-ramatroban precursor [47] and serinol [48]. Moreover, substituted aminotetralins, potential agents
used to treat Parkinson’s disease and cardiovascular disorders, have also been successfully synthesized
using an engineeredω-TA from Arthrobacter citreus [ω-TAAc] [49] and a novel (S)-selectiveω-TA from
Pseudomonas fluorescens KNK08-18 [50]. However,ω-TA-mediated transamination reactions generally
are thermodynamically limited [51]. For instance, the reported equilibrium constant of ω-TA from
Vibrio fluvialis JS17 (ω-TAVf ) for the kinetic resolution of (S)-α-MBA, using pyruvate as co-substrate, is
1135. Thus, the equilibrium is greatly shifted toward the formation of L-alanine and acetophenone,
consequently making it difficult to perform asymmetric synthesis of (S)-α-MBA without rapid product
removal and/or the use of sacrificial amines as donors [52].
Subsequently, various strategies have been applied to prevail over these limitations. For instance,
a 20-fold excess of (S)-α-MBA was used in the asymmetric synthesis of serinol-monoester, a precursor
for the synthesis of chloramphenicol, wherein the (S)-enantiomer was obtained with 92% conversion
and 92% ee, when F85L/V153A variant ofω-TAVfwas used [48]. In addition, many of theω-TAs use
L-alanine as an amine donor. Thus, the recycling or removal of pyruvate formed can help to overcome
the thermodynamic barrier of the reaction. The application of two strategies is generally used for
the removal of pyruvate co-product. (1) Use of lactose dehydrogenase (LDH) and NADH recycling
system [53], wherein pyruvate is reduced to lactate, which is recycled using glucose dehydrogenase at
the expense of cheaper substrate i.e., glucose (Figure 3B). (2) Use of alanine dehydrogenase (AlaDH) for
the effective recycling of L-alanine as amine donor has been reported to reduce the cost of amine donor
by 97%, while simultaneously decreasing the E-factor (environmental factor; the ratio of the mass of
waste per mass of product) and improving the atom efficiency [54]. However, the use of additional
enzymes and their cofactors leads to further complications of the overall biocatalytic reactions.
Although α-MBA, isopropylamine and L-alanine have been most frequently used as amine donors
in theω-TA-mediated asymmetric syntheses, more reactive amine donors are highly desirable to drive
reaction equilibrium, and to reduce the use of a high molar excess of these sacrificial amine donors
used in the biocatalytic reactions. Recently, ‘smart’ diamine donors, such as xylylenediamine (XDA)
were discovered, which is readily converted to an amino aldehyde. The subsequent intramolecular
cyclization of the amino aldehydes tautomerizes to form isoindol, which is polymerized, and can
easily be removed from the reaction mixture due to precipitation (Figure 3C) [53]. However, XDA is
not accepted by all wild-type ω-TAs, and it is not a cheaper amino donor, ultimately increasing
the cost of the biocatalytic reaction [30]. It was more recently reported that only 1.5 equiv. of
cis-but-2-ene-1,4-diamine can be used as sacrificial amine donor for the conversion of aromatic
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sec-alcohols with different substitutions in the aromatic ring to the corresponding amines in a sequential
application of laccases andω-TAs [55]. Furthermore, recyclable biogenic terminal diamines, such as
putrescine, cadaverine, and spermidine have also recently been discovered to drive the equilibrium
towards amination of ketones. Following the transamination, these bio-based diamines are converted
into reactive amino aldehydes, which spontaneously get converted to cyclic imines, thus shifting the
equilibrium towards product formation [56].
The synthesis of chiral amines using ω-TA-mediated catalysis has been explored using broad
substrate types, including linear, cyclic and aromatic ketones. Numerous research groups have
exploited this biocatalytic route for the synthesis of a wide range of pharmaceutical compounds,
their intermediates and unnatural amino acids such as beta-and gamma-amino acids [33,57].
Various methods, for instances, co-product removal using cascade enzymes, and the use of ‘smart’
amine donors to reduce the excess use of sacrificial amines, have been developed to overcome the
limitations in biocatalytic reactions employingω-TAs. Recently, Rehn et al. demonstrated the successful
use of supported liquid membrane for the in-situ product removal of (S)-α-methylbenzylamine
(MBA) produced by immobilized ω-TAAc [58]. Other strategies, such as substrate engineering [59]
and protein engineering, have also been developed for the efficient synthesis of chiral amines by
ω-TA-mediated biocatalysis.
2.3. Deracemization
While asymmetric synthesis is still the most favored approach to biocatalytic amine synthesis,
deracemization is also attractive, especially when access to racemic amines as substrates is easier
than to the corresponding prochiral ketone. In a deracemization reaction, theoretical complete
conversion and enantioselectivity is achieved by employing two stereocomplementaryω-TAs. The first
step in the deracemization process affords the formation of ≤50% enantiopure amine and the
corresponding ketone co-product by enantioselective deamination of the racemic amine. This is
followed by the asymmetric amination of the ketone by an enantiocomplementary ω-TA, forming
the optically pure amine in up to 100% yield [17]. Deracemization has been effectively used for the
synthesis of important pharmaceutical drugs, such as mexiletine, an orally effective anti-arrhythmic
drug (Figure 4) [60,61]. In this one-pot two-step process on 100 mg scale, an isolated yield of
97% with excellent enantioselectivity (>99% ee) could be achieved by the combination of two
stereocomplementary enzymes [61]. In addition, the change in an absolute configuration of the
generated product could easily be achieved and both (R)- and (S)-enantiomers can be produced by this
method, notably without compromising the isolated yield or enantioselectivity, by switching the order
of transaminases applied.
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Figure 4. Use of a deracemization strategy for the synthesis of enantiopure Mexiletine (reprinted with
permission from [61], Copyright (2009) American Chemical Society). (Reaction conditions: 50 mM
racemic substrate, 50 mM sodium pyruvate, 20 mg whole cells of E. coli expressing ω-TAs, phosphate
buffer (100 mM, pH 7.0), 1 mM PLP, 30 ◦C, 24 h).
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The application ofω-TAs in dynamic kinetic resolutions has also been reported to be very effective
for the synthesis of production of Niraparib, a potential anti-cancer drug, and the smoothened receptor
inhibitor (SMO), used in the treatment of leukemia [62,63]. Deracemization of various important
amines such as 4-phenylbutan-2-amine, a precursor for the antihypertensive dilevalol; sec-butylamine,
1-methoxy-2-propanamine and 1-cyclohexylethylamine, precursors of inhibitors of tumour necrosis
factor-α (TNF-α); and 1-phenyl-1-propylamine, a precursor of anti-depressant agent corticotropin
releasing factor type-1 receptor antagonist, and other important aromatic amines has been reported in
the literature [64,65].
3. Protein Engineering Aspects for Improved Substrate Scope ofω-Transaminase (ω-TA) Biocatalysts
In the context ofω-TAs, the scientific community has used various protein engineering aspects
for the efficient synthesis of chiral amines, to improve the substrate scope of available enzymes and
further even to alter the stereopreference of the enzymes [66]. In this section, we will discuss the recent
advances in the protein engineering aspects of transaminase-mediated biocatalysis for the synthesis of
chiral amines drugs and drug intermediates.
The knowledge obtained from the structure of variousω-TAs has established that, generally, the
active form ofω-TA is a homodimer, and the active site is positioned at the interface of the monomers,
wherein each monomer participates in the active site [67]. The substrate binding region of ω-TAs
is composed of two pockets: a large pocket that allows accommodation of substituents with rather
broad size distribution, such as small alkyl to naphthyl groups and small binding pocket allows access
to the small substituents, not exceeding that of a methyl group [48,68]. Although this characteristic
architecture of the active site limits the substrate scope, it also contributes to the high stereopreference
ofω-TAs [69]. Until very recently, the number of (R)-selectiveω-TAs was very limited and much of the
effort has been directed towards protein engineering approaches for the generation of stereospecific
ω-TAs, and to broaden their substrate scope. The first successful industrially applicable protein
engineering approach was the development of the (R)-selectiveω-TA-117 from Arthrobacter sp. for the
synthesis of the antidiabetic drug Sitagliptin [29]. The substrate ketone, pro-sitagliptin, is not a natural
substrate and could not be accepted by wild-type enzyme. Extensive computational modeling, along
with a directed evolution approach, was utilized to incorporate 27 mutations, not only in the active
site of the enzyme but also in the interface of the enzyme dimer. This active variant was used at the
pilot-scale production of Sitagliptin, wherein 92% yield with excellent enantioselectivity (>99.95% ee)
was afforded by 6 gL−1enzyme load. This improved process resulted in the reduction of total waste
produced by 19%, which was acknowledged by its achievement of the ‘Presidential Green Chemistry
Challenge Award for Greener Reaction Conditions’ in 2010 [70].
Since the successful engineering of ω-TA-117, many research groups have directed their
scientific efforts to the engineering of active site pockets for the acceptance of bulkier substrates
by TAs. For instance, the work by Midelfort et al. was directed towards making TAs amenable
biocatalysts for synthesis of β-aminoesters from the corresponding β-ketoesters. The (S)-ω-TAVf
was engineered for the synthesis of (3S,5R)-ethyl 3-amino-5-methyloctanoate; a key intermediate
in the synthesis of imagabalin, a drug candidate in Phase III clinical trials for the treatment
of generalized anxiety disorder. The final improved variant, r414, contained eight mutations
(F19W/W57F/F85A/R88K/V153A/K163F/I259V/R415F), which displayed a 60-fold increase in
initial reaction velocity for the transamination of (R)-ethyl 5-methyl 3-oxooctanoateto (3S,5R)-ethyl
3-amino-5-methyloctanoate (Figure 5) [71].
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Figure 5. Improved production of Imagablin by protein engineering of (S)-ω-TAVf [71]. (Reaction
conditions: 4.0 g of wet E. coli cells containing (S)-ω-TAVf mutant r414, 88 mL potassium phosphate
buffer (0.1 M, pH 7.0); 54 mg pyridoxal phosphate; 1 g substrate, 7.5 mL of 1 M solution of (S)-α-MBA,
30 ◦C, 24 h).
Further efforts to improve the substrate scope of (S)-ω-TAVf to accommodate the bulky
branched-chain substrates were carried out by Bornscheuer et al. [72]. In these studies, the most
suitable mutation sites and amino acid substitutions were identified by bioinformatic analysis using
3DM. The volume of the substrate binding pocket was enlarged by the creation of a library that
included mainly hydrophobic residues in the active site. The best variant containing four mutations
(L56V, W57C, F85V, V153A) was able to catalyze the asymmetric synthesis of sterically demanding
branched-chain chiral amines, which afforded complete conversion of the ketone and yielded the
corresponding amine with >99% ee, notably with a preference for the (R)-enantiomer.
In another study, (S)-ω-TAVf was engineered using a rational design strategy combining
in silico and in vitro studies for the asymmetric synthesis of (S)-1-(1,1′-biphenyl-2-yl)ethanamine
by ω-TA-mediated transamination between bulky aromatic ketone substrate 2-acetylbiphenyl
and the amine donor isopropylamine [73]. The incorporation of two mutations (W57G/R415A)
generated a mutant that showed detectable enzyme activity, and the rationally designed variant
(W57F/R88H/V153S/K163F/I259M/R415A/V422A) improved the reaction rate by >1716-fold
towards the bulky ketone 2-acetylbiphenyl, producing the corresponding (S)-amine with excellent
enantiomeric purity (>99% ee).
Since the substrate specificity of ω-TAs is largely controlled by steric constraints in the
substrate-binding pockets, bulky α-keto acids carrying a side chain bigger than an ethyl substituent
generally are not accepted byω-TAs. The (S)-selectiveω-TA from Ochrobactrum anthropic ((S)-ω-TAOa)
was engineered by employing alanine scanning mutagenesis to reduce steric constraints and thereby
to allow the small pocket to readily accept bulky substituents. Alanine substitution at residue L57
(L57A), a residue located in the large pocket, induces an altered binding orientation of a carboxyl
group of keto acids and amino acids and thus was able to provide more room for the small pocket.
This variant allowed the acceptance of bulkier substrates, 2-oxopentanoic acid, and L-norvaline and
improved the activity towards these substrates by 48-and 56-fold, respectively. The applicability of
the generated mutant was evaluated for the kinetic resolution of racemic norvaline and furthermore
to produce optically pure L- and D-norvaline by asymmetric amination of 2-oxopentanoic acid [74].
In another study, Nobili et al. carried out systematic mutagenesis study of the active site residues of
(S)-ω-TAVf to expand its substrate scope towards two bulky ketones. This group identified two active
mutants, F85L/V153A and Y150F/V153A, which showed a 30-fold increased activity in the conversion
of (S)-phenylbutylamine and (R)-phenylglycinol, respectively [68]. However, saturation mutagenesis
at the respective position in (S)-ω-TAVf did not improve the activity towards the same substrates
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studied in the previous studies, implying that the substrate specificity ofω-TA is a complex episode
and cannot be directly related from one enzyme template to another.
In a contribution to expand the substrate scope of ω-TAs, Pavlidis et al. [75] mutated a
fold class I (S)-ω-TA from Ruegeria sp. TM1040 [(S)-ω-TARu; PDB ID: 3FCR] by rational design
and identified an active variant with just four mutations (3FCR_QM; Y59W/Y87F/Y152F/T231A),
which proved sufficient for the acceptance of bulkier ketones and enabled asymmetric synthesis of
a wide set of bulky chiral amines on a preparative scale with excellent conversion, isolated yield
and stereoselectivity. This group further carried out mutational studies on (S)-ω-TARu for the
synthesis of a bridged bicyclic amine exo-3-amino-8-aza-bicyclo[3.2.1]oct-8-yl-phenyl-methanone,
a motif constituent of many neuroactive agents, from its corresponding ketone substrate [76].
Two active variants were identified (3FCR_QM/I234F) and (3FCR_QM/I234M), which exhibited
specific activity of 80 and 116 mU mg−1, respectively, while maintaining absolute stereoselectivity
compared to 45 mU mg−1 of the mutant identified in the previous studies (3FCR_QM) for the kinetic
resolution of a bicyclic amine exo-3-amino-8-aza-bicyclo[3.2.1]oct-8-yl-phenyl-methanone.
Although (S)-ω-TARu has successfully been engineered to accept aromatic (such as bicyclic)
and thus planar bulky amines, the variants active towards the substrates carrying a bulky tert-butyl
substituent adjacent to the carbonyl function, such as 2,2-dimethyl-1-phenyl-propan-1-one, were
unavailable until very recently. To address this issue, (S)-ω-TARu was engineered by introducing five
mutations [Y59W/Y87L/T231A/L382M/G429A] [77]. This active variant enabled the asymmetric
synthesis of (R)-2,2-dimethyl-1-phenylpropan-1-amine from the corresponding ketone substrate
2,2-dimethyl-1-phenyl-propan-1-one and isopropylamine as an amine donor. These studies suggested
the critical importance of amino residue Y87, as it blocks the entrance for the sterically demanding
tert-butyl moiety, and the introduction of a mutation at this position (Y87L) allowed the hydrophobic
interaction between the substrate moiety and amino acid residue at position 87, thus leading to the
accommodation of the bulky substrate [77].
Protein engineering approaches have played a crucial role in the generation of highly efficient
ω-TAs. Various approaches, such as directed evolution and rationally designed engineering of
ω-TAs, not only improved the scope for bulkier substrates but also improved their enantioselectivity.
Knowledge of the various putative sequences of protein families has successfully been used for the
identification of novel transaminases. Various approaches have been utilized for improvement in
kinetic resolution and asymmetric synthesis approaches. The removal of co-products by physical
extraction using membrane bioreactors has been successfully implemented to favor the reaction
equilibrium towards product formation. Furthermore, reaction engineering by employing cascade
reactions to remove and/or recycle the product have also found a useful role in equilibrium shift.
To this end, various ‘smart’ amine donors have been developed that allow the cyclization or the
tautomerization. Ever since the successful demonstration of protein engineering for the industrial
production of sitagliptin, various approaches of protein engineering have spurred improvement in the
substrate scope of TAs and their enantioselectivities.
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4. Establishing Stableω-TA Biocatalysts for Synthetic Applications
The synthetic applicability of TA biocatalysts can be successfully extended to industrial scale only
with the use of robust and reusable biocatalysts, which can offer excellent stability in non-physiological
conditions. The stability of any enzymatic preparation can be exemplified as its thermodynamic
stability (conformational stability of the enzyme structure), kinetic stability (stability over time)
and operational stability, which includes thermostability and stability in organic solvents [78,79].
The following sections summarize the various strategies adopted to improve the stability ofω-TAs
and thereby their applicability in the synthesis of chiral amines.
4.1. Finding Thermostable ω-TAs
Owing to their excellent stability, thermostable enzymes permit execution of the biocatalytic
reaction at higher temperatures. This results in the achievement of higher reaction rates and
furthermore to the easier removal of volatile by-products, thereby helping to shift the equilibrium of the
reaction towards product formation [11,41]. Enzymes originating from thermophilic microorganisms
naturally possess desired properties of high operational and thermodynamic stabilities [80]. Recently,
Cerioli and co-workers [81] identified a ω-TA from the halophilic bacterium Halomonas elongata
exhibiting highest activity at 50 ◦C. In addition, the enzyme activity was retained in the presence
of co-solvents up-to 20%, proving the enzyme suitable for industrial application of transamination
of poorly water-soluble substrates. Chen et al. [82] improved the operational stability of ω-TA
from Chromobacterium violaceum (ω-TACv) by the addition of additives, co-solvents, and organic
solvents, and demonstrated the first successful application ofω-TA co-immobilized with surfactants.
It was shown that the enzyme retains its active dimeric structure when it is stored in 50% glycerol,
20% methanol or 10% DMSO. Mathew et al. recently identified two thermostable ω-TAs, each
from Thermomicrobium roseum (ω-TATr) and Sphaerobacter therlmophilus(ω-TASt) respectively [33,83].
A (S)-ω-TATr showed improvement in residual activity when the enzyme was incubated for 1 h at
60 and 70 ◦C, which was attributed to the refolding of an enzyme to its natural conformation at higher
temperatures. In addition, this enzyme exhibited a broad substrate scope and could be utilized for
the synthesis of chiral amines using asymmetric synthesis and kinetic resolution approaches [83].
Another thermostable TA, (S)-ω-TASt, showed the highest activity at 60 ◦C and no loss of activity
following 1 h incubation at this temperature was noticed. It was also reported that the stability
of (S)-ω-TAS was not adversely affected in the presence of 20% DMSO, implying the industrial
potential of the enzyme [33]. More recently, Chen et al. [84] identified a thermostable ω-TA from
Geobacillus thermodenitrificans (ω-TAGt), which showed highest activity at 65◦C. The ω-TAGt also
exhibited 2.5-fold increase in activity when the enzyme was incubated for 8 h at 50 ◦C or 30 min at
60 ◦C. Most recently, Ferrandi et al. [85] discovered the novel thermostable ω-TA by exploiting the
metagenomics approach. One of the three discoveredω-TAs, B3-TA, was exceptionally thermostable
and retained 85% and 40% of the initial activity after the incubation at 80 ◦C for 5 days and 2 weeks,
respectively. B3-TA is the most thermostable naturalω-TA known till date, which also showed excellent
tolerance toward different water-miscible and water immiscible organic solvents (Table 1).
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Table 1. Selected examples of recently discovered thermostableω-TAs.
Sr. No. Source Enzyme Selectivity Strategy Used
Optimum
Temperature (◦C)
Remarks Reference
1
Halomonas elongata
DSM 2581
(S)-selective
Conserved domain
analysis
50
First study reported onω-TA from
the moderate halophile bacterium
H. elongate. The stability was
unaffected in the presence of
organic solvents.
[81]
2 Chromobacterium violaceum (S)-selective 65
The enzyme performance was
improved 5-fold by a
co-lyophilization with surfactants
[82]
3 Sphaerobacter thermophilus (S)-selective
BLAST search against
protein sequences
from thermophiles
60
The enzyme was utilized for the
stereoselective synthesis of β- and
γ- amino acids
[33]
4 Thermomicrobium roseum (S)-selective
BLAST search against
protein sequences
from thermophiles
87
Volatile inhibitory byproducts
were removed by performing
asymmetric synthesis and kinetic
resolution at high temperature
[83]
5 Geobacillus thermodenitrificans (S)-selective
BLAST search against
protein sequences
from thermophiles
65
The enzyme showed relatively
good activity toward ketoses,
suggesting its potential for
catalyzing the asymmetric
synthesis of chiral amino alcohols.
[84]
6 Hot spring metagenomes (S)-selective Metagenomics 88
The most thermostable natural
ω-TA known till date.
[85]
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4.2. Protein Engineering
In addition to its application to the improvement of the substrate scope of ω-TAs, protein
engineering approaches have also been extended to improve the operational stability of the enzymes
(Table 2). For instance, (R)-selective ω-TA-117 from Arthrobacter sp., employed in the industrial
production of sitagliptin, was engineered to improve its tolerance towards organic solvents [29].
Eleven rounds of evolution generated the optimized biocatalyst, which could afford a successful
transamination of high substrate load (50 g L−1 pro-sitagliptin ketone) at 45 ◦C, importantly,
in the presence of 50% DMSO as a co-solvent. Pannuri et al. also engineeredω-TAAc to improve its
thermostability and subsequently used it for stereoselective synthesis of chiral amines [86].
The recent structural studies of ω-TAs have established the fact that the homotetrameric
conformations of ω-TAs possess superior operational stability compared to their homodimeric
counterparts [87,88]. It has also been postulated that the structural integrity of the cofactor-ring
binding domain is a decisive factor in the operational stability of ω-TAs. The cofactor-ring motif,
positioned at the interface of monomer and dimer interface, is known to shape the bottom of the active
site and to shield the cofactor from the solvent environment. To gain deeper insights into the role of
cofactor-ring motif in the operational stability of tetramericω-TAs, Börner et al. [89] recently generated
several mutant libraries by targeting 32 amino acid residues around the active site and cofactor-ring
domains. A double mutant (Asn161Ile and Tyr164Leu) increased the resting stability of the enzyme by
11 ◦C compared to its wild-type parent enzyme. Notably, mutations introduced at these two positions
conferred an excellent operational stability in biphasic reaction system at 45 ◦C. Moreover, the addition
of third mutation (Gly51Ser) granted an additive effect in terms of thermal resistance and improved
the thermal resistance of the resting state by 4 ◦C [89].
In another study, the (R)-ω-TA from Aspergillus terreus [(R)-ω-TAAt] was recently engineered
by employing the combination of an in silico strategy and mutational studies by site-directed
mutagenesis [90]. The potential mutation sites were selected based on the folding energy calculations
and four stabilized mutants (T130M, T130F, E133F and D134L) were obtained. These studies were
successful in generating a single mutant (T130M) and double mutant (T130M/E133F), which improved
the half-life (t1/2) at 40 ◦C by ~2.2 and 3.3-fold, respectively. The mutations carried out at these
positions generated new hydrophobic clusters and increased the hydrogen bonds, thereby improving
the thermostability of the mutants compared to the wild-type protein.
Protein engineering by incorporation of noncanonical amino acids has also been proven to be
an attractive strategy to improve the stability and activity of ω-TAs [91]. Recently, Yun’s group
successfully used this approach for the improvement of enzymatic properties and thereby its
synthetic applications of (S)-ω-TAVf. The global incorporation of 3-fluorotyrosine resulted in 2.3-fold
improvement of a half-life of engineered enzyme compared to its wild-type counterpart. Furthermore,
the engineered (S)-ω-TAVf could completely convert 25 mM of acetophenone into (S)-MBA with
excellent enantioselectivity (ee >99%) in the presence of 20% DMSO (v/v), which was ~2-fold higher
than wild-typeω-TAVf [92].
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Table 2. Selected examples of application of protein engineering techniques to improve operational stability ofω-TAs.
Sr. No. Source Enzyme Selectivity Strategy Used Remarks Reference
1 Arthrobacter sp. (R)-selective
Substrate walking, modeling,
and mutation approach
11 rounds of evolution generated the
optimized biocatalyst, which could afford a
successful transamination of in the presence
of 50% DMSO as a co-solvent
[29]
2 Arthobacter citreus (S)-selective
Structure-guided
enzyme mutagenesis
The enzyme was used for the industrial
production of substituted aminotetraline
[86]
3
Novel enzyme from
c-LEcta’smetagenomic library
Semi-rational mutagenesis
32 amino acid residues were targeted around
the active site including the cofactor-ring
motif for superior operational, thermo- and
solvent stability
[89]
4 Aspergillus terreus (R)-selective
In silico design employing
B-factor and folding free
energy calculations
The optimum catalytic temperature of a
mutant T130F was increased by 10 ◦C
[90]
5 Sphaerobacter thermophilus (S)-selective
Residue-specific andsite-specific
incorporation of unnatural
amino acids
The residue-specific incorporation showed
2-fold enhancement in the half life at 70 ◦C
[91]
6 Vibrio fluvialis JS17 (S)-selective
Global incorporation of
unnatural amino acids
Mutant exhibited ~2-fold higher tolerance
towards 20% DMSO compared to wild-type
[92]
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4.3. Enzyme Immobilization
A single enzyme can differentially perform in different formulations in terms of activity and stability.
Although the cell-free, purified form of a protein is the most desirable form of any biocatalysts, the higher
purification costs limit its application on large scales. Biocatalyst in another form i.e., cell free extracts,
can also be used if the target protein is sufficiently overexpressed. However, the long-term storage
stability of the purified as well as cell free extracts is poor [12]. Therefore, use of the whole cells expressing
the biocatalyst of interest is of potential use. However, the major limitation of the use of whole cell
biocatalysts is the poor accessibility of the substrate to the enzymes located within the cells [93].
One potential approach to improve the stability of biocatalysts is their immobilization.
Immobilization is advantageous owing to its low downstream requirements, as it allows the easy
recovery of the biocatalysts and their reuse in the subsequent batch or continuous reactions [42,93,94].
Immobilization has been widely used to improve the operational and storage stability of ω-TAs
(Table 3). For instance, Koszelewski et al. [95] encapsulated the commercially available enzymes
TA-117, TA-113, TA-114 andω-TAVf using sol–gel/celite matrix for the first time. The immobilized
TA-117 exhibited excellent operational stability and retained about 78% of the initial activity after eight
repetitive uses, most importantly, without compromising the enantioselectivity. The immobilization by
covalent attachment using various support materials such as chitosan is also widely reported [96–99].
De Souza et al. [100] recently utilized cellulose for immobilization ofω-TAVf. Theω-TAVf immobilized
in the epoxy-functionalized cellulose conferred excellent temperature stability and reusability, wherein
enzyme was consistently active over the broad range of temperature from 30 to 60 ◦C and for four
repetitive cycles in the asymmetric synthesis of (S)-phenylethylamine.
The entrapment of whole cells expressing ω-TAs using natural materials such as Ca-alginate,
gelatin, or agarose has been reported. For instance, Rehn et al. compared the various methods of
immobilization of recombinant E. coli cells expressingω-TAAc. Chitosan proved to be the method of
choice for the whole-cell immobilization as it retained >90% activity after eight successive batches [42].
In another study, Cardenas-Fernandez et al. successfully overcame the diffusional limitations of
whole-cell immobilization by entrapping the permeabilized whole cells in PVA-gel (Lentikats®) [101].
While most of the non-commercial supports limit their application because of the labor-intensive
preparations prior to immobilization, commercially available ready-to-use supports such as polymeric
resins are feasible. Neto et al. [41] recently immobilized (S)-ω-TA (ATA-47) and (R)-ω-TA (Ate-TA)
using commercially available polemeric resins as enzyme carriers. Among six, two enzyme carriers
i.e., (Relizyme HA403; pore size-40–60 nm and Supabeads EC-HA; pore size-10–20 nm; both having
hexamethylamino functional groups) allowed the reuse of the preparation for 250 h of operation with
retention of more than 50% of the initial activity. In addition, the immobilized preparations increased
thermal stability, allowing storing the enzyme formore than 60 days at room temperature [41].Most recently,
Abaházi et al. [1] covalently immobilized Try60Cys mutant ofω-TACv on bisepoxide-activated polymeric
resins. The enzymemutant immobilized by linking it to polymeric resin with ethylamine function activated
with glycerol diglycidyl ether-EA-G could preserve the activity even in the high concentration of DMSO
(50% v/v). Furthermore, this enzyme preparation could be used for 19 consecutive cycles in batch mode
for the kinetic resolution of rac-4-phenylbutan-2-amine to its corresponding R-enantiomer, a precursor for
antihypertensive dilevalol, with excellent activity and selectivity (C~50%, ee > 99%).
Protein fusion tags, such as polyhistidine tags, provide an efficient protein purification by
affinity chromatography and allow the enzyme immobilization in assembling immobilized enzyme
microreactors (IEMR) [11,102,103]. IEMRs are the unique platforms for in vitro multi-enzymatic
synthetic pathways. Furthermore, recent advances in nanotechnology have provided several
nanomaterials for the efficient immobilization of the enzymes. Nanomaterials provide the large
surface area that improves the adsorption of proteins and thereby allow the separation of protein
in a low-concentration samples [104] Immobilization of ω-TAs using Ni2+-chelated polydopamine
magnetic nanoparticles [104], magnetic PVA-Fe3O4 nanoparticles [105] and MnO2 nanorods [106] has
been recently reported in the literature.
Catalysts 2018, 8, 254 15 of 25
Table 3. Selected examples of immobilization techniques used to improve the operational stability ofω-TAs.
Sr. No. Source Type of Immobilization
Support Used for
Immobilization
Comment Reference
1
Chromobacterium violaceum
(Trp60Cys mutant)
Covalent binding
bisepoxide-activated
polymeric resins
Immobilized preparation was used for 19 consecutive
reaction cycles and in media containing up to 50% (v/v)
DMSO as co-solvent in batch mode reactions.
[1]
2 (S)-selective ATA-47 Ionic interaction
Relizyme HA403
(commercial material)
Immobilized preparation retained more than 50% initial
activity for 8 cycles (each of 24 h; corresponding to more than
250 h of operation)
[41]
3 (R)-selective Ate-TA Hydrophobic
Supabeads EC-HA
(commercial material)
The immobilized preparation increased the thermal stability,
allowing storing the enzyme for more than 60 days
[41]
4 ω-TA 117 Sol–gel entrapment Celite 545
The immobilized enzyme preparation could be recycledeight
times with only moderate decrease of activity for each cycle
[95]
5 Gibberella zeae Covalent binding Modified chitosan Significant improvement in pH and temperature stability [96]
6 Neosartorya fischeri Covalent binding Modified chitosan Significant improvement in pH and temperature stability [96]
7 Aspergillus fumigatus Covalent binding Chitosan
The immobilized enzyme showed higher activity at 70 ◦C
compared to free enzyme
[97]
8 Ruegeria pomeroyi Covalent binding Chitosan The immobilized enzyme retained activity after four batches [97]
9 Vibrio fluvialis JS17 Covalent binding Chitosan
Significant improvement in stability over broad range of pH
and temperature
[99]
10 Vibrio fluvialis Covalent binding Functionalized cellulose The immobilized enzyme retained activity for four cycles [100]
11 Bradyrhizobium japonicum Affinity
Ni2+-functionalized
polydopamine
magneticna noparticles
Simultaneous purification and immobilization of the
his-tagged protein could be achieved
[104]
12 Mycobacterium vanbaalenii Covalent binding
magnetic PVA-Fe3O4
nanoparticles
The immobilized enzyme could be successfully reused for
13 times in biotransformation
[105]
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5. Cascade Reactions Involvingω-TAs
Enzymatic cascades, wherein several independent reactions proceed simultaneously, offer numerous
advantages in the production of target compounds, such as shortened synthetic routes, minimization of
the use of organic solvents, and improvement in atom efficiency [11,12]. Furthermore, the easier handling
of unstable intermediates and the control of unfavorable reaction equilibrium are added benefits of using
biocatalytic cascades [107–109]. Cascade reactions have been categorized into four main types: (1) Linear
cascades represent consecutive transformations in one-pot. (2) Parallel cascades, which are frequently
used in redox biocatalysis wherein the product formation is coupled with a simultaneously proceeding
second reaction. (3) The third type, orthogonal cascades, are closely related to parallel cascades and are
generally used to shift the reaction equilibrium towards product formation. (4) Cyclic cascades, which
are generally used for the stereoinversion processes. Readers are referred to recent reviews [107–113],
which have elegantly elaborated on the advancements achieved in the field of cascade reactions.
Multi-enzymatic cascades involvingω-TAs have been successfully used for the amination of the
hydroxyl functional groups of alcohols to their corresponding amines. For instance, Fuchs et al. [114]
utilized the cascade of galactose oxidase and ω-TAs for the amination of benzylic and cinnamic
alcohols. In the first step, alcohol substrates are converted to their corresponding aldehydes in the
presence of galactose oxidase. In the subsequent step, the transamination of aldehyde intermediates
arecatalyzed byω-TAs (Figure 6).
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Figure 6. Biocatalytic cascade employing galactose oxidase and ω-TA for the amination of
benzylic/cinnamic alcohols (reprinted from [114], with permission of The Royal Society of Chemistry).
(Reaction conditions: 50 mM substrate, 20 mg lyophilized E. coli BL21(DE3) cells over-expressing
galactose oxidase, 0.075 mg/mL 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), 20 mg,
lyophilized E. coli BL21(DE3) cells over-expressing ω-TAVf, Sodium phosphate buffer (100 mM,
pH 7.0), 1 mM PLP, 10 mM CuSO4, 7.5 mg alanine dehydrogenase, 20 U glucose dehydrogenase,
150 mM L-alanine, 120 mM (2.4 equiv) glucose, R.T., 24 h).
Similarly, an artificial redox-neutral cascade, employing alcohol dehydrogenase, alanine
dehydrogenase, andω-TA, has been recently utilized for the conversion of ether alcohol substrates to
their corresponding ether amine products [115]. Initially, alcohol ether substrates were converted to
the corresponding aldehydes or ketones using ADH from G. stearothermophilus. ω-TACv subsequently
catalyzed the amination of these intermediates, wherein AlaDH from V. proteolyticus recycled pyruvate
to L-alanine with the simultaneous regeneration of the NAD+ cofactor (Figure 7).
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Figure 7. Artificial redox-neutral cascade employing alcohol dehydrogenase, ω-TA and alanine
dehydrogenase for the synthesis of ether amines from ether alcohol substrates (reprinted from [115]
with the permission of John Wiley and Sons). (Reaction conditions: 10 mM substrate, 280 mM
ammonia, ammonium carbamate buffer (40 mM, pH 9.0), 1 mMNAD+, 0.35 mMPLP, 0.5 mM L-Alanine,
0.1 mg/mL ADH, 0.004 mg/mL Ala-DH, 0.064 mg/mLω-TACv, 30 ◦C).
Chiral amino-alcohols are known as common constituents of many natural products,
pharmaceuticals and chiral auxiliaries used in chemical syntheses [116]. For instance, a chiral
amino-triol, (2S,3R)-2-amino-1,3,4-butanetriol (ABT), is used as a precursor for the synthesis of statins
and ultimately for a HIV-protease inhibitor Nelfinavir. Gruber et al. [117] recently demonstrated a
novel 2-step-enzymatic synthesis of approach, employing transketolase andω-TA, for the synthesis of
ABT in a continuous-flow microreactor system. In the initial step, transketolase -catalyzed asymmetric
carbon-carbon bond formation between hydroxypyruvate and glycoaldehyde led to the generation
of L-Erythrulose. In the subsequent step,ω-TA-catalyzed conversion of the keto-group into a chiral
amino group generated ABT (Figure 8).
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Figure 8. Biocatalytic cascade employing transketolase and ω-TA for the synthesis of amino alcohol
(2S,3R)-2-amino-1,3,4-butanetriol (Reprinted from [117], with the permission of John Wiley and Sons).
(Reaction conditions: 50 mM substrate, 3.25 U/mL transketolase, 4.8 mM thiamine diphosphate (ThDP),
19.6 mMMgCl2, 10 mM (S)-α-MBA, 27 U/mLω-TA, 2 mM PLP, Tris-HCl buffer (100 mM, pH 9.0), R.T.).
Despite its complexity, sophisticated enzymatic cascades were recently developed for the synthesis
of pharmaceutically important alkaloid scaffolds, such as THIQs. For instance, Erdmann et al. [118]
recently reported the synthesis of 1,3,4-trisubstituted THIQs with three chiral centers by employing the
cascade of three enzymes, namely carboligase, ω-TACv and a mutant of Pictet-Spenglerase enzyme
Norcoclaurine synthase (NCS) from Thalictrum flavum. In the first reaction, carboligase catalyzed the
generation of (R)-1-hydroxy-1-(3-hydroxyphenyl)propan-2-one from3-hydroxybenzaldehyde andpyruvate
substrates. The transamination catalyzed byω-TACv generated the corresponding amino product from
(R)-1-hydroxy-1-(3-hydroxyphenyl)propan-2-one. Subsequent Pictet-Spengler condensation, catalyzed
by NCS-Tf, generated a THIQ product (1S,3S,4R)-1-benzyl-3-methyl-1,2,3,4-THIQ-4,6-diol (Figure 9).
In addition, opposite stereoselectivities of the C1-substituted-THIQs could be achieved following the
chemical cyclization by phosphate (Figure 9), providing access to both the orientations of the substituted
THIQ [118].
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Figure 9. Enzymatic and Chemo-enzymatic synthesis of 1-benzyl-THIQs employing the cascade of
carboligase, ω-TA and NCS [118]. (Reaction conditions: step 1: 10 mM substrate, HEPES buffer
(100 mM, pH 7.5), 5 mMMgCl2, 0.1 mM ThDP, 0.05 mM FAD, 20 mM sodium pyruvate, 2.5% DMSO
(v/v), 0.5 mg/mL acetohydroxy acid synthase I from E. coli (EcAHAS-I), 30 ◦C, 750 rpm; Step 2: 0.2 mM
PLP, 100 mM isopropylamine, 3.1% DMSO (v/v), 3 mg/mLω-TACv, 30 ◦C, 750 rpm; step 3 (Enzymatic):
9.5 mm phenylacetaldehyde, 2.5% DMSO (v/v), 0.5 mg/ mL NCS-Tf -A79I), 37 ◦C, 750 rpm; step 3
(Chemo-enzymatic): 10 mM bromobenzaldehyde, 200 mM potassium phosphate buffer, pH 7.0, 50 ◦C,
750 rpm).
Another Pictet-Spenglerase enzyme, Strictosidine synthase (STR), has also been employed
in the cascade consisting of ω-TAs for the synthesis of (S)-strictosidine derivatives possessing
an additional stereogenic center at C3 of the tetrahydro-β-carboline moiety [119]. In the initial
reaction, α-methyltryptamine derivatives were generated using ω-TA-catalyzed amination of
prochiral ketone substrates. Subsequent STR-catalyzed condensation of α-methyltryptamine
derivatives with secologanin formed optically pure C3-methyl-substituted strictosidine derivatives.
Furthermore, the use of stereocomplementaryω-TAs allowed the synthesis of both the enantiomers
of α-methyltryptamine derivatives, which ultimately allowed the synthesis of both the epimers of
C3-methyl-substituted strictosidine derivatives [119] (Figure 10).
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Figure 10. Biocatalytic cascade employing ω-TA and STR for the chemo-enzymatic synthesis of
C3-methyl-substituted enantiopure Strictosidine derivatives (adapted with permission from [119],
Copyright (2015) American Chemical Society). (Reaction conditions: 2 mM substrate, potassium
phosphate buffer (100 mM, pH 7.0), 10 mg lyophilized E. coli cells over-expressingω-TA, 90 mU STR,
250 mM D-or L-alanine, 150 mM ammonium formate, 1 mM PLP, 1 mM NAD+ 11 U FDH, 4 U Ala-DH,
DMSO (5%, v/v), 4 mM secologanin, 24 h, 30 ◦C).
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6. Conclusions and Prospects
The ever-increasing demands of enzyme-mediated synthesis of enantiopure amines are being
elegantly met by engineered ω-TAs. The decreasing costs of gene synthesis and the increasing
availability of the genome sequences have given access to a new pool of potentialω-TAs. Therefore, the
exploitation of these novel biocatalysts can provide a massive addition to the application of biocatalysts
for the industrial synthesis of various pharmaceuticals, fine chemicals, and other important industrial
products. This accelerated rate of biocatalyst discovery has permitted scientific community to enter a
‘golden age’ of biocatalysis[120]. Despite this progress, many of the recently-discovered enzymes still
display poor substrate tolerance profiles, making their role as routine catalysts unlikely. Nevertheless,
the recent advances in the reaction engineering such as, development of ‘smart’ amine donors, in-situ
product removal, and application of cascade reactions, have successfully addressed the major challenge
of poor reaction equilibrium towards product formation. In addition, protein engineering strategies
have played a pivotal role in expanding the substrate scope of recently discovered biocatalysts and
further in improving the thermodynamic and operational stabilities of the already-available enzymes.
The future ofω-TA biocatalysis research should also see the discovery of novel enzymes, particularly
thermostable ones, by utilizing metagenomic approaches. The application of engineeredω-TAs for
the industrial production of sitagliptin has already exhibited the synthetic potential of these potent
biocatalysts. Engineeredω-TAs will continue to develop as a competitive alternative technology to
conventional syntheses for the production of enantiomerically enriched amines.
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